Treatment of pyroptosis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11752196
APP PUB NO 20210069296A1
SERIAL NO

17026534

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1α) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1α) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of aberrant pyroptosis in the kidney, brain, liver or other organ of the body.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
JALAN RAJIV9 DUGGAN DRIVE CHISLEHURST BR7 5EP

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Beaton, Nigel London, GB 2 0
Jalan, Rajiv London, GB 25 233
Mehta, Gautam London, GB 3 3
Soffientini, Ugo London, GB 1 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 12, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 12, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 12, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00